Selective COX-2 inhibitors as anticancer agents: a patent review (2014-2018)

References

• Cronin KA, Lake AJ, Scott S, et al. annual report to the nation on the status of cancer, part i: national cancer statistics. Cancer. 2018;124(13):2785-2800. doi: 10.1002/cncr.31551.
   Google Scholar
• Xu J, Mao W. Overview of research and development for anticancer drugs. J Cancer Ther. 2016;7(10):762.
   Google Scholar
• Lee Y, Rodriguez C, Dionne R. The role of COX-2 in acute pain and the use of selective COX-2 inhibitors for acute pain relief. Curr Pharm Des. 2005;11(14):1737–1755.
   PubMed Web of Science ®Google Scholar
• Xu X-C. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs. 2002;13(2):127–137.
   PubMed Web of Science ®Google Scholar
• De Monte C, Carradori S, Gentili A, et al. Dual cyclooxygenase and carbonic anhydrase inhibition by nonsteroidal anti-inflammatory drugs for the treatment of cancer. Curr Med Chem. 2015;22(24):2812–2818.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Casini A, Mastrolorenzo A, et al. COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. Mini Rev Med Chem. 2004 Aug;4(6):625–632.
   PubMed Web of Science ®Google Scholar
• Dogne JM, Thiry A, Pratico D, et al. Dual carbonic anhydrase–cyclooxygenase-2 inhibitors. Curr Top Med Chem. 2007;7(9):885–891.
   PubMed Web of Science ®Google Scholar
• Temperini C, Cecchi A, Scozzafava A, et al. Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited—old leads for new applications? Org Biomol Chem. 2008;6(14):2499–2506.
   PubMed Web of Science ®Google Scholar
• Noma N, Fujii G, Miyamoto S, et al. impact of acetazolamide, a carbonic anhydrase inhibitor, on the development of intestinal polyps in min mice. Int J Mol Sci. 2017;18(4):851.
   Web of Science ®Google Scholar
• Singh S, Lomelino CL, Mboge MY, et al. cancer drug development of carbonic anhydrase inhibitors beyond the active site. Molecules (Basel, Switzerland). 2018 Apr 30;23:5.
   Web of Science ®Google Scholar
• Pannunzio A, Coluccia M. Cyclooxygenase-1 (COX-1) and COX-1 inhibitors in cancer: a review of oncology and medicinal chemistry literature. Pharmaceuticals. 2018;11(4):101.
   Web of Science ®Google Scholar
• Mattia C, Coluzzi F. COX-2 inhibitors: pharmacological data and adverse effects. Minerva Anestesiol. 2005;71(7–8):461–470.
   PubMedGoogle Scholar
• Davies NM, Jamali F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharm Sci. 2004 Oct 29;7(3):332–336.
   PubMed Web of Science ®Google Scholar
• Zarghi A, Arfaei S. Selective COX-2 inhibitors: a review of their structure-activity relationships. Iran J Pharm Res. 2011 Autumn; 10(4):655–683.
   PubMed Web of Science ®Google Scholar
• Mathew ST, Devi SG, Prasanth VV, et al. Efficacy and safety of COX-2 inhibitors in the clinical management of arthritis: mini review. ISRN Pharmacol. 2011;2011:480291.
   PubMedGoogle Scholar
• Syed M, Skonberg C, Hansen SH. Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria. Toxicol In Vitro. 2016 Apr;32:26–40.
   PubMed Web of Science ®Google Scholar
• Bansal SS, Joshi A, Bansal AK. New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors. Drugs Aging. 2007;24(6):441–451.
   PubMed Web of Science ®Google Scholar
• Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol. 2004;63(9):901–910.
   PubMed Web of Science ®Google Scholar
• Simon L. Arthritis: new agents herald more effective symptom management. Geriatrics (Basel, Switzerland). 1999;54(6):37–42. quiz 44.
   PubMed Web of Science ®Google Scholar
• Zatz R, Fujihara CK. Mechanisms of progressive renal disease: role of angiotensin II, cyclooxygenase products and nitric oxide. J Hypertens Suppl. 2002;20(3):S37–S44.
   PubMedGoogle Scholar
• Grosser T, Theken KN, FitzGerald GA. Cyclooxygenase inhibition: pain, inflammation, and the cardiovascular system. Clin Pharmacol Ther. 2017;102(4):611–622.
   PubMed Web of Science ®Google Scholar
• Lk D, Cf L, Jc T. Epidemiologic association between prostatitis and prostate cancer. Urology. 2002;60(1):78–83.
   Web of Science ®Google Scholar
• Lr H. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007;9(4):210.
   PubMed Web of Science ®Google Scholar
• Lm C, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860.
   PubMed Web of Science ®Google Scholar
• Yao M, Lam E, Kelly C, et al. Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer. 2004;90(3):712.
   PubMed Web of Science ®Google Scholar
• Eisinger AL, Prescott SM, Jones DA, et al. The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostaglandins Other Lipid Mediat. 2007;82(1–4):147–154.
   PubMed Web of Science ®Google Scholar
• Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946–1952.
   PubMed Web of Science ®Google Scholar
• Food U, Administration D. Pfizer, Inc.; withdrawal of approval of familial adenomatous polyposis indication for CELEBREX. 2016.
   Google Scholar
• Dai P, Li J, Ma X-P, et al. Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis. Onco Targets Ther. 2018;11:721.
   PubMed Web of Science ®Google Scholar
• Perwez Hussain S, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121(11):2373–2380.
   PubMed Web of Science ®Google Scholar
• Sobolewski C, Cerella C, Dicato M, et al. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol. 2010;2010:215158. doi: 10.1155/2010/215158.
   Google Scholar
• Stoimenov I, Helleday T. PCNA on the crossroad of cancer.Biochem Soc Trans. 2009;37(Pt 3):605-613. doi: 10.1042/BST0370605.
   Google Scholar
• de Franceschi N, Hamidi H, Alanko J, et al. Integrin traffic–the update. J Cell Sci. 2015;128(5):839–852.
   PubMed Web of Science ®Google Scholar
• Regulski M, Regulska K, Prukala W, et al. COX-2 inhibitors: a novel strategy in the management of breast cancer. Drug Discov Today. 2016 Apr;21(4):598–615.
   PubMed Web of Science ®Google Scholar
• Su CW, Zhang Y, Zhu YT. Stromal COX-2 signaling are correlated with colorectal cancer: a review. Crit Rev Oncol Hematol. 2016 Nov;107:33–38.
   PubMed Web of Science ®Google Scholar
• Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Nat Acad Sci. 1997;94(7):3336–3340.
   PubMed Web of Science ®Google Scholar
• Liu R, Xu KP, Tan GS. Cyclooxygenase-2 inhibitors in lung cancer treatment: bench to bed. Eur J Pharmacol. 2015 Dec 15;769:127–133.
   PubMed Web of Science ®Google Scholar
• Sung I-C, Huang K-H, Sung M-T, et al. The HGF/c-Met/COX-2 and Jagged1/Notch1/COX-2 pathways as molecular targets for gastric cancer treatment. J Cancer Res Pract. 2014;1(2):93–102.
   Google Scholar
• Qiu J, Shi Z, Jiang J. Cyclooxygenase-2 in glioblastoma multiforme. Drug Discov Today. 2017 Jan;22(1):148–156.
   PubMed Web of Science ®Google Scholar
• Khor L-Y, Bae K, Pollack A, et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol. 2007;8(10):912–920.
   PubMed Web of Science ®Google Scholar
• An KP, Athar M, Tang X, et al. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol. 2002 Jul;76(1):73–80.
   PubMed Web of Science ®Google Scholar
• Bernard M, Bancos S, Sime P, et al. Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des. 2008;14(21):2051–2060.
   PubMed Web of Science ®Google Scholar
• Sun H, Zhang X, Sun D, et al. COX-2 expression in ovarian cancer: an updated meta-analysis. Oncotarget. 2017;8(50):88152.
   PubMedGoogle Scholar
• Hase T, Yoshimura R, Matsuyama M, et al. Cyclooxygenase-1 and −2 in human testicular tumours. Eur J Cancer. 2003;39(14):2043–2049.
   PubMed Web of Science ®Google Scholar
• Uddin MJ, Crews BC, Xu S, et al. Antitumor activity of cytotoxic cyclooxygenase-2 inhibitors. ACS Chem Biol. 2016;11(11):3052–3060.
   PubMed Web of Science ®Google Scholar
• Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne colorectal cancer study. Cancer Res. 1988;48(15):4399–4404.
   PubMed Web of Science ®Google Scholar
• Rai A, Kumar U, Raj V, et al. Novel 1,4-benzothazines obliterate COX-2 mediated JAK-2/STAT-3 signals with potential regulation of oxidative and metabolic stress during colorectal cancer. Pharmacol Res. 2018;132:188–203.
   PubMed Web of Science ®Google Scholar
• Clària J. Cyclooxygenase-2 biology. Curr Pharm Des. 2003;9(27):2177–2190.
   PubMed Web of Science ®Google Scholar
• Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996;384(6610):644.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay D, Granados JC, Short JD, et al. Polycyclic aromatic compounds as anticancer agents: evaluation of synthesis and in vitro cytotoxicity. Oncol Lett. 2012;3(1):45–49.
   PubMed Web of Science ®Google Scholar
• Becker FF, Banik BK. Polycyclic aromatic compounds as anticancer agents: synthesis and biological evaluation of some chrysene derivatives. Bioorg Med Chem Lett. 1998;8(20):2877–2880.
   PubMed Web of Science ®Google Scholar
• Sadeghi-Aliabadi H, Aliasgharluo M, Fattahi A, et al. In vitro cytotoxic evaluation of some synthesized COX-2 inhibitor derivatives against a panel of human cancer cell lines. Res Pharm Sci. 2013;8(4):298.
   PubMedGoogle Scholar
• Yamauchi S, Wukirsari T, Ochi Y, et al. Syntheses of cytotoxic novel arctigenin derivatives bearing halogen and alkyl groups on aromatic rings. Bioorg Med Chem Lett. 2017;27(17):4199–4203.
   PubMed Web of Science ®Google Scholar
• Rodl CB, Vogt D, Kretschmer SB, et al. Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism. Eur J Med Chem. 2014 Sep 12;84:302–311.
   PubMed Web of Science ®Google Scholar
• Naaz F, Preeti Pallavi MC, Shafi S, et al. 1,2,3-triazole tethered Indole-3-glyoxamide derivatives as multiple inhibitors of 5-LOX, COX-2 & tubulin: their anti-proliferative & anti-inflammatory activity. Bioorg Chem. 2018;81:1–20.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Choi MJ, Shin JS, et al. Synthesis, biological evaluation, and docking analysis of a novel family of 1-methyl-1H-pyrrole-2,5-diones as highly potent and selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem Lett. 2014 Apr 15;24(8):1958–1962.
   PubMed Web of Science ®Google Scholar
• Galal SA, Khairat SH, Ragab FA, et al. Design, synthesis, and molecular docking study of novel quinoxalin-2(1H)-ones as anti-tumor active agents with inhibition of tyrosine kinase receptor and studying their cyclooxygenase-2 activity. Eur J Med Chem. 2014 Oct 30;86:122–132.
   PubMed Web of Science ®Google Scholar
• Pirahmadi N, Zarghi A, Salimi A, et al. beta-lactam Structured, 4-(4-(Methylsulfonyl)phenyl)-1-pentyl-3-phenoxy azetidine-2-one: selectively targets cancerous B Lymphocyte mitochondria. Anticancer Agents Med Chem. 2017;17(9):1292–1301.
   PubMed Web of Science ®Google Scholar
• Yakaiah S, Sagar Vijay Kumar P, Baby Rani P, et al. Design, synthesis and biological evaluation of novel pyrazolo-oxothiazolidine derivatives as antiproliferative agents against human lung cancer cell line A549. Bioorg Med Chem Lett. 2018 Feb 15;28(4):630–636.
   PubMed Web of Science ®Google Scholar
• Yatam S, Gundla R, Jadav SS, et al. Focused library design and synthesis of 2-mercapto benzothiazole linked 1, 2, 4-oxadiazoles as COX-2/5-LOX inhibitors. J Mol Struct. 2018;1159:193–204.
   Web of Science ®Google Scholar
• Ghatak S, Vyas A, Misra S, et al. Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, COX/LOX inhibition, molecular modeling, and insights into their cytotoxicities. Bioorg Med Chem Lett. 2014 Jan 1;24(1):317–324.
   PubMed Web of Science ®Google Scholar
• Qiu HY, Wang PF, Li Z, et al. Synthesis of dihydropyrazole sulphonamide derivatives that act as anti-cancer agents through COX-2 inhibition. Pharmacol Res. 2016;104:86–96.
   PubMed Web of Science ®Google Scholar
• El Sayed MT, El-Sharief M, Zarie ES, et al. Design, synthesis, anti-inflammatory antitumor activities, molecular modeling and molecular dynamics simulations of potential naprosyn(R) analogs as COX-1 and/or COX-2 inhibitors. Bioorg Chem. 2018;76:188–201.
   PubMed Web of Science ®Google Scholar
• El-Husseiny WM, El-Sayed MA, Abdel-Aziz NI, et al. Structural alterations based on naproxen scaffold: synthesis, evaluation of antitumor activity and COX-2 inhibition, and molecular docking. Eur J Med Chem. 2018 Oct 5;158:134–143.
   PubMed Web of Science ®Google Scholar
• Nguyen BCQ, Takahashi H, Uto Y, et al. 1,2,3-Triazolyl ester of Ketorolac: A “Click Chemistry”-based highly potent PAK1-blocking cancer-killer. Eur J Med Chem. 2017 Jan;27(126):270–276.
   Google Scholar
• Medda F, Sells E, Chang HH, et al. Synthesis and biological activity of aminophthalazines and aminopyridazines as novel inhibitors of PGE2 production in cells. Bioorg Med Chem Lett. 2013 Jan 15;23(2):528–531.
   PubMed Web of Science ®Google Scholar
• Temirak A, Shaker YM, Ragab FA, et al. Part I. Synthesis, biological evaluation and docking studies of new 2-furyl benzimidazoles as antiangiogenic agents. Eur J Med Chem. 2014 Nov;24(87):868–880.
   Google Scholar
• Mathew B, Hobrath JV, Connelly MC, et al. Diverse amide analogs of sulindac for cancer treatment and prevention. Bioorg Med Chem Lett. 2017 Oct 15;27(20):4614–4621.
   PubMed Web of Science ®Google Scholar
• Sever B, Altintop MD, Kus G, et al. Indomethacin based new triazolothiadiazine derivatives: synthesis, evaluation of their anticancer effects on T98 human glioma cell line related to COX-2 inhibition and docking studies. Eur J Med Chem. 2016 May 4;113:179–186.
   PubMed Web of Science ®Google Scholar
• Chen Z, Wang ZC, Yan XQ, et al. Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors. Bioorg Med Chem Lett. 2015 May 1;25(9):1947–1951.
   PubMed Web of Science ®Google Scholar
• Coricello A, El-Magboub A, Luna M, et al. Rational drug design and synthesis of new alpha-Santonin derivatives as potential COX-2 inhibitors. Bioorg Med Chem Lett. 2018 Apr 1;28(6):993–996.
   PubMed Web of Science ®Google Scholar
• El-Gamal MI, Oh C-H. Synthesis, in vitro antiproliferative activity, and in silico studies of fused tricyclic coumarin sulfonate derivatives. Eur J Med Chem. 2014;84:68–76.
   PubMed Web of Science ®Google Scholar
• Farzaneh S, Shahhosseini S, Arefi H, et al. Design, synthesis, and biological evaluation of new 1,3-diphenyl-3- (phenylamino)propan-1-ones as selective cyclooxygenase (COX-2) Inhibitors. Med Chem. 2018;14(7):652–659.
   PubMed Web of Science ®Google Scholar
• Regulski M, Piotrowska-Kempisty H, Prukala W, et al. Synthesis, in vitro and in silico evaluation of novel trans-stilbene analogs as potential COX-2 inhibitors. Bioorg Med Chem. 2018 Jan 1;26(1):141–151.
   PubMed Web of Science ®Google Scholar
• Gasser G, Ott I, Metzler-Nolte N. Organometallic anticancer compounds. J Med Chem. 2010;54(1):3–25.
   PubMed Web of Science ®Google Scholar
• Jaouen G, Vessières A, Top S. Ferrocifen type anti-cancer drugs. Chem Soc Rev. 2015;44(24):8802–8817.
   PubMed Web of Science ®Google Scholar
• Ren SZ, Wang ZC, Zhu D, et al. Design, synthesis and biological evaluation of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy. Eur J Med Chem. 2018 Sep 5;157:909–924.
   PubMed Web of Science ®Google Scholar
• Farzaneh S, Zeinalzadeh E, Daraei B, et al. New ferrocene compounds as selective cyclooxygenase (COX-2) inhibitors: design, synthesis, cytotoxicity, and enzyme-inhibitory activity. Anticancer Agents Med Chem. 2018;18(2):295–301.
   PubMed Web of Science ®Google Scholar
• Reiley MA, Silber BM, Chen X, inventor REILEY PHARMACEUTICALS, INC., assignee. COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS. United States patent WO 2016/111834. 2016 July 14.
   Google Scholar
• Jeon Y-W, Suh YJ. Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells. Oncol Rep. 2013;29(2):819–825.
   PubMed Web of Science ®Google Scholar
• Fantini M, Benvenuto M, Masuelli L, et al. In vitro and in vivo antitumoral effects of combinations of polyphenols, or polyphenols and anticancer drugs: perspectives on cancer treatment. Int J Mol Sci. 2015;16(5):9236–9282.
   PubMed Web of Science ®Google Scholar
• Yu C-P, Qiu R-G, Shi L, et al. Celecoxib and quercetin induce apoptosis in human hepatocarcinoma. Biomed Res. 2017;28(8):3465–3470.
   Google Scholar
• Cai H, Huang X, Xu S, et al. Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy. Eur J Med Chem. 2016 Jan 27;108:89–103.
   PubMed Web of Science ®Google Scholar
• Ren SZ, Wang ZC, Zhu XH, et al. Design and biological evaluation of novel hybrids of 1, 5-diarylpyrazole and Chrysin for selective COX-2 inhibition. Bioorg Med Chem. 2018 Aug 7;26(14):4264–4275.
   PubMed Web of Science ®Google Scholar
• Lu XY, Wang ZC, Ren SZ, et al. Coumarin sulfonamides derivatives as potent and selective COX-2 inhibitors with efficacy in suppressing cancer proliferation and metastasis. Bioorg Med Chem Lett. 2016 Aug 1;26(15):3491–3498.
   PubMed Web of Science ®Google Scholar
• Shen FQ, Wang ZC, Wu SY, et al. Synthesis of novel hybrids of pyrazole and coumarin as dual inhibitors of COX-2 and 5-LOX. Bioorg Med Chem Lett. 2017 Aug 15;27(16):3653–3660.
   PubMed Web of Science ®Google Scholar